menu

Key Considerations for G-CSF Administration in Patients with FN Risk

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Key Considerations for G-CSF Administration in Patients with FN Risk

Program Information
Recommended

Program Information

ReachMD Healthcare Image
RestartResume

Here’s what you need to keep in mind when administering granulocyte colony stimulating factors for primary prophylaxis of febrile neutropenia.

  • Sponsored by

  • Overview

    Febrile neutropenia (FN) is characterized by a low absolute neutrophil count with fever, and it's a common complication in patients receiving certain types of chemotherapy. Fortunately, agents like granulocyte colony stimulating factors (G-CSFs) can be used for primary prophylaxis of FN because they stimulate the bone marrow to produce infection-fighting white blood cells called neutrophils. But which patients should be considered for primary prophylaxis with G-CSFs, and when should G-CSFs be administered? Joining Dr. Charles Turck to answer that and other key questions is Dr. Arielle Heeke.   

    USA-OPAL-80124
Schedule29 Jan 2022
Webpack App